

mTOR-IN-1

Catalog No: tcsc1383



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg



Specifications

CAS No:

1207358-59-5

Formula:

$C_{25}H_{30}N_8O_2$

Pathway:

PI3K/Akt/mTOR

Target:

mTOR

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Observed Molecular Weight:

474.56

Product Description


mTOR-IN-1 is a remarkably selective **mTOR** inhibitor with a **K_i** of 1.5 nM. mTOR-IN-1 suppresses **mTORC1** and **mTORC2** in cellular and in vivo pharmacokinetic (PK)/pharmacodynamic (PD) experiments.

IC50 & Target: Ki: 1.5 nM (mTOR)^[1]

mTORC1, mTORC2^[1]

In Vitro: mTOR-IN-1 (Compound 12i) inhibits mTOR with a K_i of 1.5 nM, 500-fold selectivity over closely related PI3 kinases. mTOR-IN-1 inhibits NCI-PC3 and MCF7neo/Her2 cells proliferation with IC_{50} s of 150 nM and 57 nM, respectively^[2].

In Vivo: mTOR-IN-1 (Compound 8h) has high free plasma clearance in both mice (1818 mL/min/kg) and rats (1538 mL/min/kg in rat)^[1]. mTOR-IN-1 (Compounds 12i) is selected for this study due to its potency, selectivity, and favorable mouse PK profile. Plasma levels of mTOR-IN-1 6 h following oral administration in PC3 tumor-bearing mice along with the fold decreases of phosphorylated mTORC1 and -2 substrates relative to time-matched vehicle controls. mTOR-IN-1 has moderate terminal elimination half-life ($t_{1/2}$ = 1.7 h for mouse (1 mg/kg, iv)). mTOR-IN-1 achieves tumor stasis at the highest 200 mg/kg/day dose examined, which appears to also be approaching the limit of tolerability for this molecule^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!